Estée Lauder Makes Strategic Investment in Clinical Skincare Pioneer 111Skin
The Estée Lauder Companies has made a strategic minority investment in 111Skin, the London-based clinical skincare brand founded by renowned cosmetic surgeon Dr. Yannis Alexandrides. This acquisition signifies a major shift towards aesthetics-inspired beauty as part of the company’s ongoing “Beauty Reimagined” strategy.
Stéphane de La Faverie, President and CEO of The Estée Lauder Companies, praises 111Skin for its innovative approach. “111Skin exemplifies this shift, translating Dr. Alexandrides’ more than 35 years of surgical and aesthetic treatment experience into high-performance luxury skincare inspired by in-clinic treatments,” he says. The brand is celebrated for its next-generation actives, potent formulas, and proven clinical efficacy, effectively bridging the gap between cosmetic products and medical aesthetics.
This investment reflects a wider industry trend towards regenerative aesthetics and science-backed formulations. Brands are increasingly incorporating clinical insights and pharmaceutical-grade ingredients into their products. This strategic move by Estée Lauder comes amidst ongoing merger discussions with Spanish beauty giant Puig, although no final agreement has been reached yet.
Source: Cosmetics Business